Obinutuzumab, a new anti ‐CD20 antibody, and chlorambucil are active and effective in anti‐myelin‐associated glycoprotein antibody polyneuropathy

ConclusionsIn our patients, obinutuzumab was effective as a first ‐line treatment of anti‐MAG antibody polyneuropathy. CLL might have had a role in the response to therapy, but the associations might be considered in future trials.

Source: European Journal of Neurology - November 27, 2018 Category: Neurology Authors: C. Briani, A. Visentin, A. Salvalaggio, M. Cacciavillani, L. Trentin Tags: Short Communication Source Type: research